Thomas Powles

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials

  European Urology Open Science · 2025-12-19

• Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer?

  European Urology Focus · 2025-12-16 · 1 citations

• Towards biomarker-driven therapies for urothelial carcinoma

  Nature Reviews Clinical Oncology · 2025-11-27 · 4 citations

• Standardizing time-to-event reporting in single-arm BCG-unresponsive registration trials: a case for Kaplan–Meier

  Annals of Oncology · 2025-11-24

• 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis

  The Oncologist · 2025-10-01

• Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

  The Lancet Oncology · 2025-10-01 · 8 citations

• Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

  European Urology Oncology · 2025-08-19 · 2 citations

• Established and emerging biomarkers approaches in urothelial carcinoma

  Expert Review of Anticancer Therapy · 2025-08-05 · 6 citations

• Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

  ESMO Open · 2025-08-01 · 11 citations

• Perioperative durvalumab for muscle invasive bladder cancer: the start of a new chapter

  Future Oncology · 2025-07-16

• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease

  European Urology · 2025-06-03 · 5 citations

• Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.

  Journal of Clinical Oncology · 2025-05-28 · 20 citations

• Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.

  Journal of Clinical Oncology · 2025-05-28

• Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.

  Journal of Clinical Oncology · 2025-05-28

• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial

  European Urology Oncology · 2025-05-02 · 1 citations

• SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN IMPROVES EVENT-FREE SURVIVAL VERSUS BACILLUS CALMETTE-GUÉRIN AS STANDARD OF CARE IN HIGH-RISK NON- MUSCLE-INVASIVE BLADDER CANCER: PHASE 3 CREST STUDY RESULTS

  The Journal of Urology · 2025-04-25 · 2 citations

• Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Preprint

  Preprints.org · 2025-04-11 · 2 citations

• Randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma

  http://isrctn.com/ · 2025-03-28

• INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).

  Journal of Clinical Oncology · 2025-02-10 · 3 citations

• KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2025-02-10 · 2 citations